Precision's Messerschmidt Talks Immunotherapy with ASCO Post

 

Precision Oncology Chief Medical Officer Gerald Messerschmidt sits down to talk with ASCO Post‘s Ronald Piana regarding the future of immunotherapy. Dr. Messerschmidt touches on a number of topics, including immune surveillance, checkpoint inhibitors, cancer cell cloaking and the future of therapy combinations.

To read the complete article, please click here.